 KP1019, a salt of "trans"-tetrachlorobis(indazole)ruthenate(III), has entered into clinical trials.KP1019 has an octahedral structure with two "trans" N-donor indazole and four chloride ligands in the equatorial plane.It has a low solubility in water, which makes it difficult to transport in the bloodstream.